About the Company
we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALEC News
Alector’s Clinical Progress and Financial Health Anchor Buy Recommendation
In a report released on March 5, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Alector (ALEC – Research Report), ...
Alector Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.8. Alector, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Alector, Inc.: Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb. 27, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported fourth quarter and full year 2023 financial ...
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Good day and thank you for standing by. Welcome to Alector’s Q4 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now ...
Loading the latest forecasts...